奥锐特(605116.SH)：全资子公司获得药品注册批件

Core Viewpoint - Aorite (605116.SH) has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1] Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite, has been granted a drug registration certificate for the combined packaging of estradiol tablets and dydrogesterone tablets [1] - The drug, developed by Abbott B.V., is intended for the treatment of menopausal syndrome caused by natural or surgical menopause [1] - The combined packaging was initially approved for import in 2015 under the brand name "Feminine" [1] Group 2 - The new drug registration is classified under the new registration method for chemical drugs, which is expected to improve the company's competitive position in the pharmaceutical market [1] - The approval of this product for domestic sales is anticipated to have a positive effect on the company's financial performance [1]